Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • MSF: Untangling the web of antiretroviral price reductions, 17th Edition

    This 17th edition of Untangling the Web of Antiretroviral Price Reductions is a departure from recent previous years. The information is presented in a new, shorter format focusing on a few key drugs as well as future regimens, along with an analysis of the current opportunities, challenges and threats faced in keeping the price of ARVs down.

    08 August 2014 | MSF
  • Even With Obamacare, HIV Patients Are Shouldering A Huge Portion Of Their Treatment Costs

    While the Affordable Care Act (ACA) forbids insurance companies from refusing coverage to people with preexisting conditions, many providers have categorized special drugs — including those that treat HIV — so that patients shoulder as much as 50 percent of the total cost.

    08 August 2014 | ThinkProgress
  • Gilead's Sovaldi soars with sales of $3.48 billion

    An excellent day for Gilead Sciences has seen the US biotech post record-breaking sales of its hepatitis C pill Sovaldi and approval in the USA for Zydelig to treat three types of blood cancer.

    25 July 2014 | Pharma Times
  • US govt demands more pricing info on Gilead HCV pill

    The cost of Gilead Sciences’ hepatitis C pill Sovaldi is once again under the spotlight with the US Senate Finance Committee requesting detailed pricing information.

    15 July 2014 | Pharma Times
  • Obamacare's Surprising HIV Drug Demand

    The Affordable Care Act has established basic core health requirements for insurance plans offered in the U.S. that support those diagnosed with life-threatening chronic diseases, including HIV. As a result, Express Scripts has reported that demand for drugs used to treat HIV and prevent HIV transmission grew in the first quarter because of rising enrollment in both marketplace plans and the expansion of Medicaid in many states.

    14 July 2014 | Motley Fool
  • Zombie patents

    Drug companies are adept at extending the lifespan of patents, at consumers’ expense

    25 June 2014 | The Economist
  • HCV drug out of the running

    The German pharmaceutical giant Boehringer Ingelheim is stopping development of faldaprevir, its hepatitis C virus (HCV) drug.

    23 June 2014 | MedPage Today
  • A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

    In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

    23 June 2014 | Reuters
  • UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

    The US Food and Drug Administration (FDA) has granted priority review for AbbVie’s experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug’s application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. AbbVie’s new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV. [Article source:]

    19 June 2014 | CDC
  • Dolutegravir in HIV-1 infection: Added benefit in adult patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

    19 June 2014 | Science Daily
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.